FAP, June 19 (Xinhua)-- recently, the company received a notice of acceptance approved and issued by the State Drug Administration, and the application for clinical trials of JS207 for injection was accepted. JS207 is a recombinant humanized anti-PD-1 and VEGF bispecific antibody independently developed by the company, which is mainly used in the treatment of advanced malignant tumors.